| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:47 UTC |
|---|
| HMDB ID | HMDB0014911 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Etoposide |
|---|
| Description | Etoposide, also known as vepesid or VP-16, belongs to the class of organic compounds known as podophyllotoxins. These are tetralin lignans in which the benzene moiety of the tetralin skeleton is fused to a 1,3-dioxolane and the cyclohexane is fused to a butyrolactone (pyrrolidin-2-one). Etoposide is a drug. Within humans, etoposide participates in a number of enzymatic reactions. In particular, etoposide can be converted into etoposide ortho-quinone; which is mediated by the enzymes prostaglandin g/h synthase 1 and prostaglandin g/h synthase 2. In addition, etoposide and uridine diphosphate glucuronic acid can be converted into etoposide glucuronide and uridine 5'-diphosphate; which is mediated by the enzyme UDP-glucuronosyltransferase 1-1. In humans, etoposide is involved in etoposide metabolism pathway. Etoposide is formally rated as a carcinogen (by IARC 1) and is also a potentially toxic compound. Etoposide is used as a form of chemotherapy for cancers such as Kaposi's sarcoma, Ewing's sarcoma, lung cancer, testicular cancer, lymphoma, nonlymphocytic leukemia, and glioblastoma multiforme. It is given intravenously (IV) or orally in capsule or tablet form. It is believed to work by damaging DNA. Etoposide was approved for medical use in the United States in 1983. They can include low blood cell counts, vomiting, loss of appetite, diarrhea, hair loss, and fever. |
|---|
| Structure | [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-Etoposide | ChEBI | | 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) | ChEBI | | 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside | ChEBI | | 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one | ChEBI | | Eposin | ChEBI | | Etopophos | ChEBI | | Etoposido | ChEBI | | Etoposidum | ChEBI | | Lastet | ChEBI | | Toposar | ChEBI | | trans-Etoposide | ChEBI | | Vepesid | ChEBI | | VP-16 | ChEBI | | 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside) | Generator | | 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside) | Generator | | 4-Demethylepipodophyllotoxin b-D-ethylideneglucoside | Generator | | 4-Demethylepipodophyllotoxin β-D-ethylideneglucoside | Generator | | 9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one | Generator | | 9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one | Generator | | Baxter oncology brand OF etoposide | HMDB | | Bristol myers brand OF etoposide | HMDB | | Bristol-myers squibb brand OF etoposide | HMDB | | Demethyl epipodophyllotoxin ethylidine glucoside | HMDB | | Etomedac | HMDB | | Etoposide teva | HMDB | | Exitop | HMDB | | Pierre fabre brand OF etoposide | HMDB | | Bristol myers squibb brand OF etoposide | HMDB | | Bristol-myers brand OF etoposide | HMDB | | Celltop | HMDB | | Etoposide pierre fabre | HMDB | | Etoposide, (5a alpha)-isomer | HMDB | | Etoposide, (5a alpha,9 alpha)-isomer | HMDB | | Etoposide, alpha-D-glucopyranosyl isomer | HMDB | | Ferrer brand OF etoposide | HMDB | | Lemery brand OF etoposide | HMDB | | Onkoworks brand OF etoposide | HMDB | | Sanfer brand OF etoposide | HMDB | | Vépéside sandoz | HMDB | | Ribosepharm brand OF etoposide | HMDB | | Baxter brand OF etoposide | HMDB | | Eposide | HMDB | | Eto gry | HMDB | | Eto-gry | HMDB | | Etoposide, (5S)-isomer | HMDB | | Etoposido ferrer farma | HMDB | | Gry brand OF etoposide | HMDB | | Novartis brand OF etoposide | HMDB | | Onkoposid | HMDB | | Pharmachemie brand OF etoposide | HMDB | | Riboposid | HMDB | | Tedec meiji brand OF etoposide | HMDB | | Etopos | HMDB | | Etoposide, alpha D glucopyranosyl isomer | HMDB | | Medac brand OF etoposide | HMDB | | Prasfarma brand OF etoposide | HMDB | | Teva brand OF etoposide | HMDB | | VP 16 | HMDB | | Vépéside-sandoz | HMDB | | alpha-D-Glucopyranosyl isomer etoposide | HMDB | | Teva, etoposide | HMDB |
|
|---|
| Chemical Formula | C29H32O13 |
|---|
| Average Molecular Weight | 588.5566 |
|---|
| Monoisotopic Molecular Weight | 588.18429111 |
|---|
| IUPAC Name | (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one |
|---|
| Traditional Name | (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one |
|---|
| CAS Registry Number | 33419-42-0 |
|---|
| SMILES | [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O |
|---|
| InChI Identifier | InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 |
|---|
| InChI Key | VJJPUSNTGOMMGY-MRVIYFEKSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Tetrahydroisoquinolines |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Tetrahydroisoquinolines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Tetrahydroisoquinoline
- 3-piperidinecarboxamide
- Piperidinecarboxamide
- Anisole
- Alkyl aryl ether
- Aralkylamine
- Benzenoid
- Piperidine
- Tertiary carboxylic acid amide
- Tertiary aliphatic amine
- Amino acid or derivatives
- Tertiary amine
- Carboxamide group
- Carboxylic acid ester
- Azacycle
- Carboxylic acid derivative
- Ether
- Monocarboxylic acid or derivatives
- Hydrocarbon derivative
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Organopnictogen compound
- Carbonyl group
- Organic nitrogen compound
- Organic oxide
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 236 - 251 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.98 g/L | Not Available | | LogP | 1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.94 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.1081 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.23 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 63.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2594.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 186.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 173.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 170.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 82.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 436.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 539.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 173.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1043.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 462.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1363.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 348.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 337.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 282.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 194.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 58.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Etoposide,1TMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4537.9 | Semi standard non polar | 33892256 | | Etoposide,1TMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4479.3 | Semi standard non polar | 33892256 | | Etoposide,1TMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4497.7 | Semi standard non polar | 33892256 | | Etoposide,2TMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4441.5 | Semi standard non polar | 33892256 | | Etoposide,2TMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4462.7 | Semi standard non polar | 33892256 | | Etoposide,2TMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4439.1 | Semi standard non polar | 33892256 | | Etoposide,3TMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4411.9 | Semi standard non polar | 33892256 | | Etoposide,1TBDMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C(C)(C)C | 4735.7 | Semi standard non polar | 33892256 | | Etoposide,1TBDMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4682.0 | Semi standard non polar | 33892256 | | Etoposide,1TBDMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4696.6 | Semi standard non polar | 33892256 | | Etoposide,2TBDMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C(C)(C)C | 4853.1 | Semi standard non polar | 33892256 | | Etoposide,2TBDMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C(C)(C)C | 4874.3 | Semi standard non polar | 33892256 | | Etoposide,2TBDMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O[Si](C)(C)C(C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4859.1 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (Non-derivatized) - 70eV, Positive | splash10-0bvi-1901070000-74ac7d5d623bed96366e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (1 TMS) - 70eV, Positive | splash10-0mm1-2900107000-099107e3dc57314671ef | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS ("Etoposide,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-qTof , Positive-QTOF | splash10-004r-0690000000-25202a61d19d3dfaed8b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-004r-0090420000-e5d6bcd633116e0553a0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-004i-0190000000-ac64a57347a9295be5dc | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-004r-0590000000-e0e45774111103754c46 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-002r-0980000000-ccf595459b4b1988d77a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-002r-0950000000-4d3313053107615d463a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 30V, Positive-QTOF | splash10-004r-0590000000-e653736b252cc5e2e795 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 40V, Positive-QTOF | splash10-002r-0980000000-48f8ee63240c179183f6 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 10V, Positive-QTOF | splash10-004r-0090420000-4257cbcff5646216f202 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-004r-0590000000-8c7420414be0c3746aff | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-002r-0091540000-94d46ba9cac17da0c456 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 40V, Positive-QTOF | splash10-000i-0930000000-d9d8244725f2e57fce96 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 35V, Negative-QTOF | splash10-0019-0397150000-e467d625bbc856208c08 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-000i-0930000000-2f7ed12e16b6771697e6 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-004i-0290010000-9da8eeb575b398d3bdbd | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-000i-0930000000-d15ca68c1981073da181 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 50V, Positive-QTOF | splash10-002r-0950000000-4d3313053107615d463a | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 35V, Positive-QTOF | splash10-004i-0390000000-b642957170b052134776 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 10V, Positive-QTOF | splash10-002r-0091670000-9a34ca7c7757308b4693 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 10V, Positive-QTOF | splash10-0uei-0106690000-bd98e3ad1ce23f0413c0 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 20V, Positive-QTOF | splash10-0ue9-0119510000-51cff21db98c0ed7effd | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 40V, Positive-QTOF | splash10-0ue9-0219300000-8bb469d4a7eadf8f5308 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 10V, Negative-QTOF | splash10-000j-1306090000-5791526d6f416ac328bf | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 20V, Negative-QTOF | splash10-000t-2009030000-3ed5cbe07a1ce3f87bf6 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 40V, Negative-QTOF | splash10-000t-2009000000-41d7c2765f3c44df7f34 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
|
|---|